Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Skye Bioscience, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:02.334 Ladies and gentlemen, thank you for standing by. 00:00:02.334 -- 00:00:05.858 My name is Desiree and I will be your conference operator today. 00:00:05.858 -- 00:00:11.185 At this time, I would like to welcome everyone to the Sky Bioscience 3rd Quarter 2024 00:00:11.185 -- 00:00:15.810 Earnings Call. All lines have been placed on mute to prevent any background noise. 00:00:15.810 -- 00:00:20.376 After the speaker's remarks, there will be a question and answer session. 00:00:20.376 -- 00:00:25.442 I would now like to turn the conference over to Bernie Hertel, Head of Investor Relations. 00:00:25.442 -- 00:00:27.883 Please go ahead. 00:00:30.777 -- 00:00:34.342 Hello, and thank you all for participating in today's call. 00:00:34.342 -- 00:00:39.610 Joining me today is Puneet Dhillon, Sky's President and CEO, and Caitlin Arsenault, 00:00:39.610 -- 00:00:41.814 Sky's CFO. 00:00:41.814 -- 00:00:45.900 Before we begin, I'd like to caution that comments made during this conference call will 00:00:45.900 -- 00:00:49.645 contain forward-looking statements under the safe harbor provisions of the U.S. 00:00:49.645 -- 00:00:53.431 Private Securities Litigation Reform Act of 1995, 00:00:53.431 -- 00:00:58.118 including statements about Sky's expectations regarding its development activities, timelines, 00:00:58.118 -- 00:01:00.207 and milestones. 00:01:00.207 -- 00:01:03.691 Forward-looking statements are subject to risks and uncertainties that could cause actual 00:01:03.691 -- 00:01:08.556 results to differ materially and adversely, and reported results should not be considered 00:01:08.556 -- 00:01:12.580 as an indication of future performance. These forward-looking statements speak only as 00:01:12.580 -- 00:01:16.585 of today's date, and t...